Part I and Part II A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of KTN3379 in Adult Subjects With Advanced Tumors Alone or With Chemotherapy.
Phase of Trial: Phase I
Latest Information Update: 26 Jul 2017
Price : $35 *
At a glance
- Drugs CDX-3379 (Primary) ; Cetuximab; Erlotinib; Trastuzumab; Vemurafenib
- Indications Advanced breast cancer; Colon cancer; Gastric cancer; Head and neck cancer; Malignant melanoma; Non-small cell lung cancer; Solid tumours
- Focus Adverse reactions
- Sponsors Celldex Therapeutics Inc; Kolltan Pharmaceuticals
- 21 Jul 2017 Status changed from active, no longer recruiting to completed.
- 06 Apr 2017 Planned End Date changed from 1 Jun 2017 to 31 Dec 2017.
- 06 Apr 2017 Planned primary completion date changed from 1 Mar 2017 to 28 Apr 2017.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History